GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 15:00:00 CEST | Press release
New Diligent Market Intelligence report finds succession costs rising as boards compete for scarce leadership talent and compensation committees face sharper investor scrutiny Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligen
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 15:00:00 CEST | Press release
Calls to Miro’s MCP server surge past 16 million; MCP jumps the developer niche with individuals in non-engineering roles now among the majority embracing the technology Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by
NTT DATA Launches ‘Intact, intelligent action.’ to Protect Fragile Places and Advance Sustainability Commitments29.9.2026 15:00:00 CEST | Press release
Global initiative will combine awareness, technology and stewardship to support fragile places around the world. Program will help translate sustainability commitments into practical actions. In the initiative’s first chapter, NTT DATA employees will join Antarctic expedition led by Robert Swan, OBE, on the 40th anniversary of his first South Pole expedition. NTT DATA, a global leader in AI, digital business and technology services, today announced “Intact, intelligent action.” This global initiative is designed to help people and organizations translate sustainability commitments into meaningful action. The effort combines awareness, technology and stewardship in support of some of the world’s most treasured yet fragile places. Antarctica will be the first chapter. From November 25 to December 2, 2026, a dozen NTT DATA employees will join polar explorer Robert Swan and his 2041 Leadership on the Edge expedition aboard the Magellan Explorer. With the Antarctic Peninsula and nearby isla
I-SEC Optimizes Airport Security Workforce Planning with Gurobi and Syntro29.9.2026 15:00:00 CEST | Press release
I-SEC navigates growing complexity with optimization—improving efficiency and ensuring regulatory compliance while keeping employee needs in mind. Gurobi Optimization, LLC, the leader in decision intelligence technology, and its partner Syntro, a provider of workforce scheduling solutions, are helping organizations like I-SEC, an international provider of airport security services, make better operational decisions in increasingly complex and highly regulated operating environments. As organizations face growing pressure to balance labor costs, regulatory requirements, service levels, and employee needs, many are turning to mathematical optimization to improve operational decision making. Airport security workforce planning is particularly complex, requiring organizations to align staffing levels with changing passenger volumes while adhering to strict regulations, accounting for required breaks and certifications, and ensuring coverage across multiple locations and checkpoints. Workin
ACIC Equipment President Patrice Pelletier to Attend CPHI Milan 202629.9.2026 15:00:00 CEST | Press release
ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help customers move projects from molecule to market. At the heart of ACIC Equipment's offering is a carefully selected network of leading technology partners, combined with ACIC's integration expertise and North American commercial and technical support. Together, they give pharmaceutical manufacturers access to specialized technologies across radiopharmaceutical production, aseptic processing, sterilization and contamination control, formulation and pure-fluid systems, filling and inspection, freeze drying, cleanrooms, packaging, vacuu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom